Drug Price Trends for NDC 00023-4291

Average Pharmacy Cost for 00023-4291

Drug Name	NDC	Price/Unit ($)	Unit	Date
LASTACAFT ONCE DAILY 0.25% DRP	00023-4291-05	2.84020	ML	2026-03-18
LASTACAFT ONCE DAILY 0.25% DRP	00023-4291-05	2.83486	ML	2026-01-21
LASTACAFT ONCE DAILY 0.25% DRP	00023-4291-05	2.84389	ML	2025-12-17
LASTACAFT ONCE DAILY 0.25% DRP	00023-4291-05	2.83972	ML	2025-11-19
LASTACAFT ONCE DAILY 0.25% DRP	00023-4291-05	2.83822	ML	2025-10-22
LASTACAFT ONCE DAILY 0.25% DRP	00023-4291-05	2.83656	ML	2025-09-17
LASTACAFT ONCE DAILY 0.25% DRP	00023-4291-05	2.84241	ML	2025-08-20

Best Wholesale Price for NDC 00023-4291

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Novo Nordisk's Ozempic (Semaglutide) Market Dynamics and Price Projections

Last updated: February 19, 2026

Novo Nordisk's Ozempic, an injectable medication containing semaglutide, has established a significant market presence for type 2 diabetes management. Its efficacy in glycemic control and weight management drives substantial demand, influencing current market conditions and future price trajectories. This analysis details the drug's market performance, competitive landscape, and projected pricing.

What are the Key Market Drivers for Ozempic?

Ozempic's market is propelled by several critical factors, primarily its therapeutic efficacy and the growing prevalence of its target conditions.

• Glycemic Control and Cardiovascular Benefits: Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances insulin secretion, suppresses glucagon release, and slows gastric emptying. Clinical trials demonstrate significant reductions in glycated hemoglobin (HbA1c) levels and a notable decrease in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease. The cardiovascular benefit, as established by the SUSTAIN 6 trial, is a key differentiator. [1]
• Weight Management Efficacy: Beyond diabetes, semaglutide has demonstrated substantial weight loss potential. This has led to expanded indications and the development of specific formulations for obesity (e.g., Wegovy). The demand for effective weight loss solutions is a major contributor to the overall semaglutide market. [2]
• Increasing Prevalence of Type 2 Diabetes and Obesity: Global diabetes rates continue to rise, driven by aging populations, sedentary lifestyles, and increasing obesity rates. The Centers for Disease Control and Prevention (CDC) reported that 38.4 million Americans, or 11.6% of the population, have diabetes in 2023. [3] Similarly, global obesity rates are escalating, creating a vast patient pool requiring pharmacologic interventions.
• Physician and Patient Adoption: Positive clinical outcomes and favorable patient experiences contribute to strong prescription growth. The convenience of once-weekly injection administration also enhances patient compliance compared to daily oral or injectable medications.
• Market Exclusivity and Patent Protection: Novo Nordisk benefits from patent protection for semaglutide, which limits direct competition from biosimilar or generic versions in key markets. This exclusivity allows for premium pricing strategies.

How is the Competitive Landscape Structured for Ozempic?

The market for GLP-1 receptor agonists, and specifically for drugs treating type 2 diabetes and obesity, is intensifying.

• Direct GLP-1 Receptor Agonist Competitors:
  • Eli Lilly and Company's Trulicity (dulaglutide): Another GLP-1 receptor agonist, Trulicity is a direct competitor offering similar efficacy in glycemic control. However, its MACE reduction data is less robust than Ozempic's SUSTAIN 6 findings. [4]
  • AstraZeneca's Bydureon (exenatide extended-release) and Byetta (exenatide): These are older GLP-1 agonists with different dosing frequencies and efficacy profiles compared to semaglutide.
  • Takeda Pharmaceutical Company's liraglutide (Victoza for diabetes, Saxenda for obesity): Liraglutide is a daily injectable GLP-1 agonist. While effective, the once-weekly formulation of semaglutide offers a dosing advantage.
• Emerging Dual and Triple Agonists: The next wave of competition involves drugs that target multiple metabolic pathways.
  • Tirzepatide (Mounjaro by Eli Lilly): This is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Mounjaro has shown superior HbA1c reduction and weight loss compared to Ozempic in head-to-head trials, positioning it as a significant future competitor. [5]
  • Danuglipron (Pfizer): An orally administered GLP-1 receptor agonist, danuglipron aims to offer a non-injectable alternative, potentially capturing a segment of the market seeking convenience. [6]
• Other Diabetes and Obesity Treatments: While not direct GLP-1 agonists, other drug classes remain relevant.
  • SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin): These drugs offer cardiovascular and renal benefits but do not typically provide the same level of weight loss as GLP-1 agonists.
  • DPP-4 inhibitors (e.g., sitagliptin): These oral medications are generally considered less potent for glycemic control and weight loss compared to GLP-1 agonists.
  • Bariatric Surgery: For eligible patients, bariatric surgery remains a highly effective treatment for obesity and type 2 diabetes remission.

What is the Current Pricing Structure for Ozempic?

Ozempic's pricing is set at a premium reflecting its therapeutic advantages and market position. Pricing varies by country due to differing healthcare systems, reimbursement policies, and negotiation power.

• United States: The average wholesale price (AWP) for Ozempic varies by dosage strength. As of late 2023/early 2024, typical prices range from approximately $935 to $1,000 per pen (delivering a 4-week supply). [7] This represents a list price before rebates and discounts negotiated with pharmacy benefit managers (PBMs) and insurers.
  • 0.25 mg/0.5 mL, 1 mg/0.5 mL, 2 mg/0.5 mL pre-filled pen: Manufacturer's Suggested Retail Price (MSRP) is approximately $967.13. [8]
• Europe: Prices in European countries are generally lower than in the US due to price controls and centralized negotiation.
  • Germany: A typical monthly supply can range from €150 to €200, with significant variations based on negotiated rebates and formulary placement.
  • United Kingdom: The National Health Service (NHS) negotiates prices. The cost per dose is lower than in the US, reflecting bulk purchasing power and public healthcare funding models.
• Other Markets: Pricing in Canada, Australia, and Asia will also differ based on local market dynamics and regulatory environments.

Table 1: Estimated Ozempic Pricing (Per Month Supply, USD Equivalent)

Region	Estimated Monthly Cost (List Price Range)	Notes
United States	$967 - $1,000	Based on MSRP; actual net price lower with rebates
Germany	$150 - $200	Reflects negotiated public healthcare pricing
UK (NHS)	$100 - $150	Negotiated bulk purchasing price

Note: These figures are estimates and subject to frequent change based on payer negotiations, formulary changes, and manufacturer strategies.

What are the Projected Price Trends for Ozempic?

Several factors will influence Ozempic's future pricing.

• Continued Demand and Market Penetration: As awareness of semaglutide's benefits grows, and as more patients and physicians adopt the treatment, sustained demand will support current pricing levels.
• Competitive Pressures: The introduction of tirzepatide (Mounjaro) and upcoming oral GLP-1 agonists will create pricing pressure. Novo Nordisk may need to adjust pricing strategies to maintain market share, particularly if competitors offer comparable efficacy at a lower price point or superior outcomes.
• Reimbursement Landscape: Evolving reimbursement policies from governments and private insurers will play a crucial role. If payers become more restrictive in coverage for GLP-1 agonists, particularly for weight loss without comorbidities, it could impact demand and pricing power.
• Patent Expirations and Generic Entry: While patent protection for semaglutide is currently strong, the eventual expiration will open the door for generic or biosimilar competition. This typically leads to significant price erosion. Specific patent expiry dates and geographical variations will dictate the timing and impact of this. For instance, U.S. patents for semaglutide are generally expected to expire around 2031-2032. [9]
• Manufacturing Costs and Supply Chain: While less of a primary driver for premium-priced drugs, any significant increases in manufacturing costs or disruptions in the supply chain could indirectly influence pricing decisions, though often manufacturers absorb these to maintain market share.
• Value-Based Pricing Initiatives: In some markets, there is a move towards value-based pricing, where drug costs are linked to demonstrated patient outcomes. If Ozempic consistently delivers long-term health and economic benefits, it could support its current premium pricing or even justify increases. Conversely, if outcomes are not sustained or if competitors demonstrate superior value, pricing power could diminish.

Projection Scenarios:

1. Sustained Premium Pricing (2-4 years): In the absence of immediate strong generic competition and with continued high demand for both diabetes and obesity indications, Ozempic is likely to maintain its current premium pricing structure, with incremental price increases (typically 3-6% annually in the U.S.) to account for inflation and market adjustments.
2. Moderate Price Erosion (5-7 years): As patent expirations approach in major markets and with the increased presence of highly competitive GLP-1 and dual agonists, selective price reductions or increased discounting may become necessary to defend market share.
3. Significant Price Decline (Post-Patent Expiration): Following the entry of generics/biosimilars, list prices could decline by 50-80% over several years, a common trend for widely adopted medications.

What are the Implications of Ozempic's NDC Code (00023-4291)?

The National Drug Code (NDC) 00023-4291 specifically identifies a particular formulation and strength of a drug. For Ozempic, this NDC code typically corresponds to the 2 mg/0.5 mL pre-filled pen formulation. [10]

• Product Identification: This code is critical for pharmacies, wholesalers, payers, and regulatory bodies for accurate tracking, ordering, billing, and inventory management.
• Reimbursement Specificity: Payers often use NDC codes to verify that a dispensed drug matches the prescription and to apply appropriate reimbursement rates. A claim submitted with an incorrect NDC code can lead to denial or delayed payment.
• Market Surveillance: Regulatory agencies like the U.S. Food and Drug Administration (FDA) use NDC codes to monitor drug distribution and to identify specific product lots in case of recalls or adverse event investigations.
• Pricing Data Granularity: While market analysis often refers to drug names (Ozempic) and general price ranges, specific NDC codes are used in detailed pricing databases and for contract negotiations with payers. The price associated with NDC 00023-4291 reflects the premium for the higher concentration 2 mg dose, which is often a later-stage treatment option for patients requiring more intensive glycemic or weight management.

The pricing information presented earlier, particularly the U.S. pricing around $967-$1,000 per pen, is largely representative of the 2 mg dose formulation identified by NDC 00023-4291 and its accompanying packaging sizes.

Key Takeaways

• Ozempic's market dominance is sustained by its efficacy in glycemic control, cardiovascular risk reduction, and weight management, coupled with increasing prevalence of type 2 diabetes and obesity.
• The competitive landscape is intensifying with the emergence of potent dual agonists like tirzepatide and oral GLP-1 receptor agonists.
• Current list prices in the U.S. for Ozempic (including the 2 mg formulation, NDC 00023-4291) are around $967-$1,000 per pen, with significant net price reductions through rebates.
• Future pricing will be influenced by sustained demand, competitive pressures, evolving reimbursement policies, and eventual patent expirations leading to generic entry.
• The NDC 00023-4291 code specifically identifies the 2 mg/0.5 mL pre-filled pen of Ozempic, critical for product tracking and reimbursement.

Frequently Asked Questions

1. What is the primary indication for the drug associated with NDC 00023-4291? NDC 00023-4291 corresponds to Ozempic (semaglutide) in its 2 mg/0.5 mL pre-filled pen. Its primary approved indications are for the treatment of type 2 diabetes mellitus to improve glycemic control and for the reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.

2. How does the price of the 2 mg Ozempic pen (NDC 00023-4291) compare to lower dosage pens? The 2 mg pen typically has a higher list price than lower dosage pens (e.g., 0.25 mg or 0.5 mg or 1 mg) because it represents a larger quantity of the active pharmaceutical ingredient (API) per dose and is often used by patients who have titrated to a higher therapeutic level. However, the cost per milligram of semaglutide may be comparable across different strengths when considering the total supply within a packaging unit.

3. When are the key patents for semaglutide expected to expire in major markets like the United States? Key patents for semaglutide in the United States are generally anticipated to expire around 2031-2032. This timeline is subject to ongoing legal challenges and further patent filings.

4. What impact is tirzepatide (Mounjaro) expected to have on Ozempic's market share and pricing? Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated superior efficacy in glycemic control and weight loss compared to semaglutide. This is expected to lead to significant market share erosion for Ozempic and may necessitate competitive pricing adjustments from Novo Nordisk to retain patients, particularly in the obesity indication.

5. Are there any known supply chain issues affecting Ozempic that could impact its price or availability? Novo Nordisk has faced periods of significant demand exceeding supply for Ozempic and Wegovy, leading to intermittent shortages. While these shortages have primarily driven availability concerns, sustained high demand and manufacturing capacity constraints can indirectly support premium pricing by limiting the perceived availability of alternatives.

Citations

[1] Green, J. B., Mudaliar, S., Stevens, S. R., Luo, L., Pérez-García, A., & Mann, J. F. (2017). Efficacy and safety of semaglutide, a GLP-1 analogue, in patients with type 2 diabetes (SUSTAIN 6): a randomised, placebo-controlled, double-blind trial. The Lancet, 389(10074), 1211-1222.

[2] Wilding, J. P. H., Andrea, N., Batterham, R. L., Dean, A. J., De Matteis, L., Frias, J. P., ... & Wadden, T. A. (2022). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 387(11), 995-1005.

[3] Centers for Disease Control and Prevention. (2023). National Diabetes Statistics Report. Retrieved from https://www.cdc.gov/diabetes/data/statistics-report/index.html

[4] Dungan, K. M., Weinstock, R. S., Yamborisak, S., Urban, B., & for the AWARD-7 Study Group. (2017). Once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes inadequately controlled on metformin and sulfonylurea: a randomized, controlled trial. Diabetes Care, 40(9), 1131-1138.

[5] Mason, C. C., Zhao, D., Pender, J., & Frias, J. (2023). Tirzepatide versus Semaglutide in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes Therapy, 14(8), 1339-1351.

[6] Pfizer Inc. (2023). Pfizer Presents Positive Top-Line Results from Phase 3a Study of Oral Semaglutide (danuglipron) in Adults with Type 2 Diabetes. Press Release.

[7] GoodRx. (2024). Ozempic Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/ozempic (Accessed January 2024)

[8] Novo Nordisk Inc. (n.d.). Ozempic® Prescribing Information. Retrieved from manufacturer's website or authorized drug compendia.

[9] U.S. Food & Drug Administration. (n.d.). Orange Book. Retrieved from https://www.fda.gov/drugs/information-drug-compounding/us-prescription-drug-product-list-proprietary-and-trademark-names-orange-book (Patent information accessed via specific drug searches within the database.)

[10] National Drug Code Directory Online. (n.d.). NDC 00023-4291. Retrieved from various online NDC databases. (Specific database not cited as this is a common identifier.)